Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.
作者信息
Wiestner Adrian
机构信息
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
出版信息
J Clin Oncol. 2013 Jan 1;31(1):128-30. doi: 10.1200/JCO.2012.44.4281. Epub 2012 Oct 8.
PMID:23045586
Abstract
摘要
Zotero 插件